Classic Familial Adenomatous Polyposis Treatment Market Outlook:
Classic Familial Adenomatous Polyposis Treatment Market size was valued at USD 1.4 billion in 2024 and is projected to reach USD 4.1 billion by the end of 2037, rising at a CAGR of 8.9% during the forecast period, 2025-2037. In 2025, the industry size of classic familial adenomatous polyposis treatment is estimated at USD 1.5 billion.
According to NIH 2024, the global patient pool for classic familial adenomatous polyposis treatment market is projected at 1 in 7,010 to 1 in over 21,990 live births. The annual diagnosed cases are approximately 31,000 to 49,000. Further, the supply chain demand is driven by surgical interventions and NSAID-based chemoprevention with APIs primarily obtained from U.S., EU, and India institutions that have received FDA approval. Medical devices are manufactured by top companies such as J&J, Medtronic, and Stryker, which are mostly situated in Ireland, Mexico, and China. Meanwhile, the Consumer Price Index for the classic familial adenomatous polyposis treatment market is increasing by 7.0% and the Producer Price Index is increasing by 4.5% YoY, reflecting the supply chain inflation.
The trade for FAP treatment components in global is completely relied on EU and North America. The U.S. imports nearly USD 221.7 million every year in NSAID APIs, especially from India and Germany. Whereas China's shipment averages 7.9%, as per the WTO. R&D investments has reached USD 851 million in FAP therapies in 2024 with 66% assigned to gene editing trials and 25.7% to minimally invasive surgical robotics, as per NIH report. The manufacturing of medical devices, especially robotic surgical systems and laparoscopic instruments, is centered in China, Mexico, and Ireland. Although 40.6% of endoscope exports worldwide come from China, which is USD 2.8 billion in 2024, regulatory scrutiny has led to tighter import restrictions on devices from China in the US and the EU, as per the FDA report in 2024.
